Caffeine Blues_ Wake Up to the Hidden Dangers of America's #1 Drug ( PDFDrive )

by Неизвестный

  138

  A. Mauskop, B. T. Altura, R. Q. Cracco et al., “Chronic Daily Headache—One Disease or Two? Diagnostic Role of Serum Ionized Magnesium,”

  Cephalalgia, February 1994;14(1):24–28. (back to text)

  139

  H. C. Diener, J. Dichgans, E. Scholz et al., “Analgesic-induced Chronic Headache: Long-term Results of Withdrawal Therapy,” Journal of Neurology, January 1989;236(1):9–14. (back to text)

  140

  A. H. Elkind, “Drug Abuse and Headache,” Medical Clinics of North America, May 1991;75(3):717–32. (back to text)

  141

  A. Panconesi, P. L. Del Bianco, C. Curradi et al., “Headache Caused by Analgesic and/or Ergotamine Abuse,” Clinica Terapeutica, May 15, 1991;137(3):169–83. (back to text)

  142

  J. R. Hughes, S. T. Higgins, W. K. Bickel et al., “Caffeine Selfadministration, Withdrawal, and Adverse Effects among Coffee Drinkers,”

  Archives of General Psychiatry, July 1991;48(7):611–17. (back to text) 143

  M. van Dusseldorp and M. B. Katan, “Headache Caused by Caffeine Withdrawal among Moderate Coffee Drinkers Switched from Ordinary to Decaffeinated Coffee: A 12-week Double-Blind Trial,” British Medical Journal, June 16, 1990; 300(6739): 1558–59. (back to text)

  144

  P. L. Cerrato, “Headaches? Change Your Diet,” RN, May 1993;56(5):69–71.

  (back to text)

  145

  R. R. Griffiths, “Caffeine Abstinence Effects in Humans,” Nida Research Monograph, 1989;95:129–30. (back to text)

  146

  M. J. Shirlow and C. D. Mathers, “A Study of Caffeine Consumption and Symptoms: Indigestion, Palpitations, Tremor, Headache and Insomnia,”

  International Journal of Epidemiology, June 1985;14(2):239–48. (back to text) 147

  E. Susman, “‘Alarm Clock Headaches’ Cured by Coffee,” Medical Tribune News Service, June 13, 1997. (back to text)

  148

  H. Jaggy and E. Koch, “Chemistry and Biology of Alkylphenols from Ginkgo bilo-ba,” L. Pharmazie, October 1997;52(10):735–38. (back to text) 149

  J. Haase, P. Halama, and R. Horr, “Effectiveness of Brief Infusions with Ginkgo biloba Special Extract in Dementia of the Vascular and Alzheimer Type,” Zeitschrift fur Gtmntogie und Geriatrie, July 1996;29(4):302–09. (back to text)

  150

  M. Fennelly, D. C. Galletly, and G. I. Purdei, “Is Caffeine Withdrawal the Mechanism of Postoperative Headache?” Anesthesia and Analgesia, April 1991;72(4):449–53. (back to text)

  151

  J. G. Weber, J. T Klindworth, J. J. Arnold et al., “Prophylactic Intravenous Administration of Caffeine and Recovery after Ambulatory Surgical Procedures,” Mayo Clinic Proceedings, July 1997;72(7):621–26. (back to text) 152

  Neuhauser-Berthold, S. Beine, S. C. Verwied et al., “Coffee Consumption and Total Body Water Homeostasis as Measured by Fluid Balance and Bioelectrical Impedance Analysis,” Annals of Nutrition and Metabolism, 1997;41(1):29–36. (back to text)

  153

  L. M. Burke, “Nutrition for Post-exercise Recovery,” Australian Journal of Science and Medicine in Sport, March 1997;29(1):3–10. (back to text) 154

  “Effect of Environmental Temperature on the Toxicity of Caffeine and Dextroam-phetamine in Mice,” Journal of Pharmacology and Experimental Therapeutics, January 1970;171(1):153–58. (back to text) 155

  P. J. Muller and J. Vernikos-Danellis, “Alteration in Drug Toxicity by Environmental Variables,” Proceedings of the Western Pharmacologic Society, 1968;11:52–53. (back to text)

  156

  B. K. Park and N. R. Kitteringham, “Assessment of Enzyme Induction and Enzyme Inhibition in Humans: Toxicological Implications,” Xenobiotica,

  November 1990;20(11):1171–85. (back to text)

  157

  Y. Ohsaki, S. Ishida, T. Fujikane et al., “Combination Effect of Caffeine and Cisplatin on a Cisplatin Resistanc Human Lung Cancer Cell Line,” Gan To Kagaku Ryoho, July 1990:17(7): 1339–43. (back to text)

  158

  J. A. Carrillo and J. Benitz, “CYP1A2 Activity, Gender and Smoking as Variables Influencing the Toxicity of Caffeine,” British Journal of Clinical Pharmacology, June 1996;41(6):605–08. (back to text)

  159

  H. Shear, S. P. Spielberg, D. M. Grant et al., “Differences in Metabolism of Sulfonamides Predisposing to Idiosyncratic Toxicity,” Annals of Internal Medicine, August 1986;105(2):179–84. (back to text)

  160

  M. Rieder, N. H. Shear, A. Kanee et al., “Prominence of Slow Acetylator Phenotype among Patients with Sulfonamide Hypersensitivity Reactions,”

  Clinical Pharmacology and Therapeutics, January 1991:49(1): 13–17. (back to text)

  161

  J. E. Trosko and H. Y. Chu, “Inhibition of Repair of UV-damaged DNAby Caffeine and Mutation Induction in Chinese Hamster Cells,” ChemicoBiological Interactions, 1973:6:317–32. (back to text) 162

  A. Antoccia, R. Ricordy, P. Maraschio et al., “Chromosomal Sensitivity to Clasto-genic Agents and Cell Cycle Perturbations in Nijmegen Breakage Syndrome Lym-phoblastoid Cell Lines,” International Journal of Radiation Biology, January 1997;71(l):4l–49. (back to text)

  163

  P. J. Donovan and J. A. DiPaolo, “Caffeine Enhancement of Chemical Carcinogen-induced Transformation of Cultured Syrian Hamster Cells,” Cancer Research, 1974:34:2720–27. (back to text)

  164

  L. L. Anderson, C. C. Lau, E. J. Gtacely et al., “Enhancement of 1311mediated Cytotoxicity by Caffeine,” Gynecologic Oncology, May 1997;65(2):253–57. (back to text)

  165

  C. Petit, “Wake Up and Smell Health Benefits of Fresh Coffee,” San Francisco Chronicle, April 14, 1997. (back to text)

  166

  X. Shi, N. S. Dalai, and A. C. Jain, “Antioxidant Behaviour of Caffeine: Efficient Scavenging of Hydroxyl Radicals,” Food and Chemical Toxicology, January 1991;29(l):1–6 (back to text)

  167

  T. P. Devasagayam, J. P. Kamat, H. Mohan et al., “Caffeine as an

  Antioxidant: Inhibition of Lipid Peroxidation Induced by Reactive Oxygen Species,” Biochemica et Biophysica Acta, June 13, 1996;1282(1):63–70. (back to text)

  168

  K. P. Wright, Jr., P. Badia, B. L. Myers et al., “Caffeine and Light Effects on Nighttime Melatonin and Temperature Levels in Sleep-deprived Humans,”

  Brain Research, January 30, 1997;747(1):78–84. (back to text) 169

  P. C. Konturek, S. J. Konturek, T. Brzozowski et al., “Gastroprotective Activity of Melatonin and Its Precursor, L-tryptophan, against Stress-induced and Ischaemia-induced Lesions Is Mediated by Scavenge of Oxygen Radicals,”

  Scandinavian Journal of Gastroenterology, May 1997;32(5):433–38. (back to text)

  170

  W. U. Mullet, T. Bauch, A. Wojcik et al., “Comet Assay Studies Indicate that Caffeine-mediated Increase in Radiation Risk of Embryos Is Due to Inhibition of DNA Repair,” Mutagenesis, January 1996;11(1):57–60. (back to text) 171

  L. J. McIntosh and R. M. Sapolsky, “Glucocorticoids May Enhance Oxygen Radical-mediated Neurotoxicity,” Neurotoxicology, 1996;17(3–4):873–82. (back to text)

  172

  V. V. Frolkis, “Stress-age Syndrome,” Mechanisms of Ageing and Development, June 1993;69(1–2):93–107. (back to text)

  173

  S. Hoyer, “Age-related Changes in Cerebral Oxidative Metabolism: Implications for Drug Therapy,” Drugs and Aging, March 1995;6(3):210–18.

  (back to text)

  174

  R. M. Sapolsky, “Why Stress Is Bad for Your Brain,” Science, August 9, 1996;273(5276):749–50. (back to text)

  175

  G. Gatti, R. Cavallo, M. L. Sartori et al., “Inhibition by Cortisol of Human Natural Killer (NK) Cell hcavny” Journal of Steroid Biochemistry, January 1987;26(1):49–58. (back to text)

  176

  J. E. Blalock et al., “The Pituitary-adtenocortical Axis and the Immune System,” Clinical Endocrin
ology and Metabolism, 1985;14(4):1021. (back to text)

  177

  H. J. Naurath, E. Joosten, R. Riezler et al., “Effects of Vitamin B12, Folate, and Vitamin B6 Supplements in Elderly People with Normal Serum Vitamin Concentrations,” Lancet, July 8, 1995;346(8967):85–89. (back to text)

  178

  H. E. Sauberlich, “Implications of Nutritional Status on Human Biochemistry, Physiology, and Health,” Clinical Biochemistry, April 1984;17(2):132–42. (back to text)

  179

  G. Schmid-Ott, R. Jacobs, B. Jager et al., “Stress-induced Endocrine and Immuno-logical Changes in Psoriasis Patients and Healthy Controls: A Preliminary Study,” Psychotherapy and Psychosomatics, 1998;67(1):37–42.

  (back to text)

  180

  D. Christensen, “Diabetes at All-time High in U.S.,” Medical Tribune News Service, October 30, 1997. (back to text)

  181

  L. Vergauwen, P. Hespel, and E. A. Richter, “Adenosine Receptors Mediate Synergistic Stimulation of Glucose Uptake and Transport by Insulin and by Contractions in Rat Skeletal Muscle,” Journal of Clinical Investigation, March 1994;93(3):974–81. (back to text)

  182

  M. Sachs and H. Forster, “Effect of Caffeine on Various Metabolic Parameters In Vivo,” Zeitschrift fur Emahrungswissenschaft, September 1984;23(3):181–205. (back to text)

  183

  J. Portugal-Alvarez, A. Zamarron, J. Yanguela et al., “Lipolysis Induced by Coffee and Tobacco: Its Modification by Insulin,” Journal of Pharmacy and Pharmacology, 1973;25:668–69. (back to text)

  184

  O. Vaccaro, D. Ingrosso, A. Rivellese et al., “Moderate Hyperhomocysteinaemia and Retinopathy in Insulin-dependent Diabetes,”

  Lancet, April 12, 1997; 349(9058):1102–03. (back to text) 185

  S. Neugenbauer, T. Baba, K. Kurokawa et al., “Defective Homocysteine Metabolism as a Risk Factor for Diabetic Retinopathy,” Lancet, February 1997;349(9050):473–74. (back to text)

  186

  C. Lehman, J. Rodin, B. S. McEwen et al., “Impact of Environmental Stress on the Expression of Insulin-dependent Diabetes Mellitus,” Behavioral Neuroscience, 1991;105:241–45. (back to text)

  187

  K. Raikkonen, L. Keltikangas-Jarvinen, H. Aldercreutz et al., “Psychosocial Stress and the Insulin Resistance Syndrome,” Metabolism, 1996;45:1533–38.

  (back to text)

  188

  J. Tuomilehto, E. Tuomilehto-Wolf, R. LaPorte et al., “Coffee Consumption as Trigger for Insulin Dependent Diabetes Mellitus in Childhood,” British

  Medical Journal, 1990;300(6725):642–43. (back to text) 189

  D. Kerr, R. S. Sherwin, F. Pavalkis et al., “Effect of Caffeine on the Recognition of and Responses to Hypoglycemia in Humans,” Annals of Internal Medicine, October 15, 1993;119(8):799–804. (back to text) 190

  P. McAdam, “Caffeine May Trigger Hypoglycemia,” Medical Tribune, 1993; 34(21):21. (back to text)

  191

  Ibid. (back to text)

  192

  F. K. Goodwin, “Behavioral Stress Reactivity Related to Arthritis Susceptibility?” Journal of the American Medical Association, 1992;267(7):910.

  (back to text)

  193

  J. B. Corcuff, P. Lafranque, P. Henry et al., “Isolated Cortiocotroph Insufficiency Associated to Myasthenia Gravis,” Journal of Endocrinology Investigation, December 1997:20(11):669–71. (back to text) 194

  D. Buchwald, J. Umali, M. Stene, “Insulin-like Growth FactorI (Somatomedin C) Levels in Chronic Fatigue Syndrome and Fibromyalgia,”

  Journal of Rheumatology, April 1996;23(4):739–42. (back to text) 195

  R. G. Lahita, “The Connective Tissue Diseases and the Overall Influence of Gender,” International Journal of Fertility and Menopausal Studies, MarchApril 1996;41(2):156–65. (back to text) 196

  R. F. van Vollenhoven, L. M. Morabito, E. G. Engleman et al., “Treatment of Systemic Lupus Erythematosus with Dehydroepiandrosterone: 50 Patients Treated up to 12 Months,” Journal of Rheumatology, February 1998;25(2):285–89. (back to text)

  197

  M. Kodama, T. Kodama, and M. Murakami, “The Value of the Dehydroepiandrosterone-annexed Vitamin C Infusion Treatment in the Clinical Control of Chronic Fatigue Syndrome (CFS) I: A Pilot Study of the New Vitamin C Infusion Treatment,” In Vivo, November 1996;10(6):575–84. (back to text)

  198

  S. J. Pollard, S. L. Spector, S. W. Yancey et al., “Salmeterol versus Theophylline in the Treatment of Asthma,” Annals of Allergy, Asthma and Immunology, May 1997;78(5):457–64. (back to text)

  199

  A. V. Lubischer and L. M. Lucas, “Monitoring Theophylline Therapy to Prevent Toxicity,” American Journal of Health, June 1, 1996;53(11):1292–94.

  (back to text)

  200

  J. T. Barr, G. E. Schumacher, D. B. Luks et al., “MildTheophylline-related Adverse Reactions and Serum Theophylline Concentration,” American Journal of Hospital Pharmacy, November 1, 1994;51(21):2688–92. (back to text) 201

  B. C. Bandyopadhyay and M. K. Poddar, “Theophylline-induced Changes in Mammalian Adenosine Deaminase Activity and Corticosterone Status: Possible Relation to Immune Response,” Methods and Findings in Experimental and Clinical Pharmacology, April 1997;19(3):181–84. (back to text) 202

  H. Segawa and Y. Iikura, “Clinical Effects of Theophylline in the Therapy of Intractable Asthmatic Children II: Theophylline Therapy and Behavior Problems in Children with Asthma” (in Japanese), Arerugi, October 1990;39(10):1427–36.

  (back to text)

  203

  K. L. Franson, D. P. Hay, V. Neppe et al., “Drug-induced Seizures in the Elderly: Causative Agents and Optimal Management,” Drugs and Aging, July 1995;7(1):38–48. (back to text)

  204

  L A. Coskey, J. Bitting, and M. D. Roth, “Inhibition of Natural Killer Cell Activity by Therapeutic Levels of Theophylline,” American Journal of Respiratory Cell and Molecular Biology, December 1993;9(6):659–65. (back to text)

  205

  T. Caballero, C. Garcia-Ara, C. Pascual et al., “Urticaria Induced by Caffeine,” Journal of Investigational Allergology and Clinical Immunology, May 1993;3(3):160–62. (back to text)

  206

  L. J. Crofford, S. R. Pillemer, K. T. Kalogeras et al., “HypothalamicPituitary-Adrenal Axis Perturbations in Patients with Fibromyalgia,” Arthritis and Rheumatism, November 1994;37(11):1583–92. (back to text) 207

  E. N. Griep, J. W. Boersma, and E. R. de Kloet, “Altered Reactivity of the HypothalamicPituitary-Adrenal Axis in the Primary Fibromyalgia Syndrome,”

  Journal of Rheumatology, March 1993;20(3):469–74. (back to text) 208

  L. J. Crofford, N. C. Engleberg, and M. A. Demitrack, “Neurohormonal Perturbations in Fibromyalgia,” Baillieres Clinical Rheumatology, May 1996;10(2):365–78. (back to text)

  209

  J. C. van Denderen, J. W. Boersma, P. Zeinstra et al., “Physiological Effects of Exhaustive Physical Exercise in Primary Fibromyalgia Syndrome (PFS): Is

  PFS a Disorder of Neuroendocrine Reactivity?” Scandinavian Journal of Rheumatology, 1992;21(1):35–37. (back to text)

  210

  M. Kennedy and D. T. Felson, “A Prospective Long-term Study of Fibromyalgia Syndrome,” Arthritis and Rheumatism, April 1996;39(4):682–85.

  (back to text)

  211

  “Fibromyalgia,” in S. Margolis and H. Moses (eds.), The Johns Hopkins Medical Handbook (New York: Random House), pp. 371–75. (back to text) 212

  J. Bearn, T. Allain, P. Coskeran et al., “Neuroendocrine Responses to Dfenfluramine and Insulin-induced Hypoglycemia in Chronic Fatigue Syndrome,”

  Biological Psychiatry, February 15, 1995;37(4):245–52. (back to text) 213

  P. Strickland, R. Morriss, A. Wearden et al., “A Comparison of Salivary Cortisol in Chronic Fatigue Syndrome, Community Depression and Healthy Controls,” Journal of Affective Disorders, January 1998;47(1–3):191–94. (back to text)

&nb
sp; 214

  L. V. Scott and T. G. Dinan, “Urinary Free Cortisol Excretion in Chronic Fatigue Syndrome, Major Depression and in Healthy Volunteers,” Journal of Affective Disorders, January 1998;47(1–3):49–54. (back to text) 215

  W. M. Jefferies, “Mild Adrenocortical Deficiency, Chronic Allergies, Autoimmune Disorders and the Chronic Fatigue Syndrome: A Continuation of the Cortisone Story,” Medical Hypothesis, March 1994;42(3):183–89. (back to text)

  216

  M. Krisiloff, “Solving Urinary Problems,” Let’s Live, October 1997;100.

  (back to text)

  217

  M. Krisiloff; personal communication. (back to text)

  218

  T. D. Moon, L. Hagen, and D. M. Heisey, “Urinary Symptomatology in Younger Men,” Urology, November 1997;50(5):700–03. (back to text) 219

  P. C. Albertsen, “Urologic ‘Nuisances’: How to Work Up and Relieve Men’s Symptoms,” Geriatrics, February 1997;52(2):46–50. (back to text) 220

  M. L. Slattery and D. W. West, “Smoking, Alcohol, Coffee, Tea, Caffeine, and Theobromine: Risk of Prostate Cancer in Utah (United States),” Cancer Causes and Control November 1993;4(6):559–63. (back to text) 221